2025-02-15 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**0. Executive Summary:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  This report analyzes MRK's performance against the S&P 500 (VOO), recent price movements, key financial indicators, and recent earnings.  The analysis reveals significant underperformance relative to the market, coupled with concerning recent price trends and mixed financial indicators.


**1. Performance vs. S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading research-driven pharmaceutical company.

* **MRK Cumulative Return:** 36.60%
* **VOO Cumulative Return:** 121.84%
* **Return Difference:** -85.2%  (MRK significantly underperformed VOO.)
* **Relative Deviation:** 0.0 (This means MRK's underperformance relative to VOO is at its lowest historical point based on the provided data. Note that this metric only uses minimum and maximum values from the provided data.)

The Alpha and Beta analysis shows inconsistent performance relative to the market (VOO), with periods of significant outperformance and underperformance.  The high Beta values (generally above 1) suggest that MRK's stock price is highly sensitive to market movements.  The inconsistent Alpha values indicate periods where MRK's performance has been both better and worse than predicted by market movements.


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.1 | 110.1 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 154.1 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 188.4 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 174.8 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 177.9 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 265.8 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 268.4 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 251.7 |
| 2023-2025  | -50.0% | 15.6% | 0.2 | 210.0 |


**2. Recent Price Movement:**

* **Closing Price:** $83.01
* **Previous Close:** $84.42
* **Change:** -$1.67 (a significant daily drop)
* **5-Day Moving Average:** $85.21
* **20-Day Moving Average:** $92.75
* **60-Day Moving Average:** $97.45

The price is below all three moving averages, indicating a downtrend.


**3. Technical Indicators:**

* **RSI:** 12.95 (Extremely oversold; typically, values below 30 suggest oversold conditions.)
* **PPO:** -1.25 (Negative value suggesting bearish momentum.)
* **20-Day Relative Deviation Change:** -0.6 (Indicates a recent downward trend.)
* **Expected Return (2+ years):** 750.7% (This exceptionally high value needs further clarification regarding its calculation and assumptions, as it seems unrealistic.)
* **Price Change:** The significant daily price drop (-$1.67) indicates a notable bearish event.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | $1.25  | $16.66 B     |
| 2024-08-05 | $2.15  | $16.11 B     |
| 2024-05-03 | $1.88  | $15.78 B     |
| 2023-11-03 | $1.87  | $15.96 B     |
| 2024-11-06 | $1.87  | $15.96 B     | *(Duplicate entry?)*


There seems to be a duplicated entry, and overall, EPS is volatile with a recent decline. Revenue shows relative stability, but the EPS drop signals concerns regarding profitability.  Further investigation is needed to understand the drivers of this volatility.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |


Revenue shows a generally upward trend, but profit margin is slightly decreasing.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-09-30 | $44.50B    | 7.09%         |
| 2024-06-30 | $43.58B    | 12.52%        |
| 2024-03-31 | $40.36B    | 11.80%        |
| 2023-12-31 | $37.58B    | -3.26%        |


Equity shows growth but ROE is volatile, with a significant negative value in Q4 2023. This needs further investigation.


**6. Overall Analysis:**

MRK's performance has significantly lagged the S&P 500 over the period analyzed. Recent price action suggests a downtrend, confirmed by technical indicators showing oversold conditions and negative momentum.  Earnings show some volatility, with a recent decline in EPS despite stable revenue.  While financial information indicates generally positive trends in revenue and equity, the inconsistent ROE and declining EPS raise concerns about profitability.  The extremely high projected return needs significant clarification.  Further detailed analysis is required to fully understand the underlying factors driving MRK's performance and to assess the validity of the projected return.  The provided data raises red flags, and deeper research into company-specific news and future outlook is essential before making any investment decision.
